Cohance Lifesciences Peer Comparison

NSE: COHANCE | BSE: 543064

₹438.00

₹-1.95 (-0.44%)

As on 18-Sep-2026IST

Market cap

₹16,760 Cr

Revenue (TTM)

₹2,142 Cr

P/E Ratio

157.8

P/B Ratio

4.4

Div. Yield

0 %

Edit

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	16,760	33,911	29,031	28,149	27,692
Revenue (₹ Cr)	2,142	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	58.53	414.00	288.22	387.35	-371.81
Net Margin (%)	2.69	11.23	14.79	26.01	-3.93
RoE (%)	3.29	8.38	29.77	25.18	-3.85
Price to Earnings	157.77	82.91	100.73	72.88	--
Price-To-Book	4.35	6.74	21.63	16.31	3.46

Income Statement (₹ Cr)

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	2,141.50	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	2,173.67	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	1,825.36	2,792.00	1,485.56	919.25	8,195.15
EBITDA	316.14	772.00	450.24	542.56	1,010.13
Depreciation	191.73	226.00	50.83	37.68	857.51
EBIT	124.41	546.00	399.41	504.88	152.62
Interest	33.80	217.00	40.84	3.77	342.73
Other Income	32.17	122.00	12.78	27.45	244.31
Exceptional Items	-21.37	12.00	0.00	0.00	-216.88
Profit before Tax	101.41	463.00	371.35	528.56	-162.68
Provision for Tax	42.88	49.00	83.14	141.21	209.13
Profit after Tax	58.53	414.00	288.22	387.35	-371.81

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	3,911.29	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	47.70	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	1,049.88	1,712.00	202.03	42.40	5,044.14
Current Liabilities	645.93	1,622.00	835.87	230.82	4,758.28
Total Liabilities	5,727.00	8,578.00	2,326.71	1,983.96	17,723.32

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	3,581.55	5,343.00	519.60	1,026.85	10,211.52
Current Assets	1,796.26	2,606.00	1,681.81	881.27	7,191.66
Total Assets	5,727.00	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	169.67	2,125.00	259.37	26.49	5,495.48
Net Current Assets	1,150.33	984.00	845.94	650.46	2,433.38
Contingent Liabilities	53.31	768.26	19.09	17.25	95.72

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	368.32	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-254.57	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	-165.15	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	-51.40	95.00	78.39	30.33	787.59

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	6.12	6.79	29.22	32.42	1.24
ROE (%)	3.29	8.38	29.77	25.18	-3.85
ROA (%)	1.34	4.94	24.77	21.93	-2.21
EBIT Margin (%)	5.81	15.32	20.63	34.54	1.66
Net Margin (%)	2.69	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-19.79	18.37	46.65	40.90	0.78
EBIT Growth (%)	-79.38	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-87.14	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-81.67	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	9.14	13.47	144.31	26.03	0.33

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	132.13	85.10	99.18	72.88	-88.50
Price / Book Value	4.35	6.74	21.63	16.31	3.46
Dividend Yield (%)	0.00	0.00	0.09	0.07	0.00
EV/EBITDA	52.52	45.82	64.29	51.52	31.51
Market Cap (₹ Cr)	11,550.78	19,071.62	12,753.19	20,944.75	18,108.89

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.01	0.31	0.11	0.02	0.53
Short term debt to equity ratio	0.02	0.09	0.05	0.02	0.09
Current Ratio	2.78	1.61	2.01	3.82	1.51
Quick Ratio	1.91	1.06	1.14	2.82	0.87
Interest Coverage	4.00	3.13	10.09	141.16	0.53

	Cohance Lifesciences	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	31.80	16.50	26.28	24.80	23.44
Asset Turnover	0.49	0.43	1.66	0.83	0.55
Receivable days	116.90	58.75	40.13	88.98	78.20
Inventory Days	82.83	75.82	60.29	56.04	93.30
Payable days	153.58	186.21	232.47	99.95	226.14
Cash Conversion Cycle	46.15	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.